Suven Life Sciences has enclosed News Release of the company titled ‘Suven Life Sciences to Present Five Scientific Posters, Including Global Phase-3 Masupirdine Study Updates and Usmarapride Phase-2 clinical development program at Alzheimer's Association International Conference (A Global Forum to Advance Dementia Science) AAIC-2026 during 12-15 July, 2026 in London, UK’.
The above information is a part of company’s filings submitted to BSE.